ULTRAGENYX PHARMACEUTICAL INC. Available-for-sale Securities, Amortized Cost Basis
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Available-for-sale Securities, Amortized Cost Basis of $918.66 million as of 2021-09-30, per its 10-Q filed 2021-11-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2021-11-03
- 2021-09-30: Available-for-sale Securities, Amortized Cost Basis $918.66M.
- 2021-06-30: Available-for-sale Securities, Amortized Cost Basis $941.39M.
- 2021-03-31: Available-for-sale Securities, Amortized Cost Basis $1.02B.
- 2020-12-31: Available-for-sale Securities, Amortized Cost Basis $1.17B.
| Period end | Available-for-sale Securities, Amortized Cost Basis | Available-for-sale Securities, Amortized Cost Basis as first filed |
|---|---|---|
| 2021-09-30 | $918.66M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $941.39M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $1.02B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $1.17B 10-Q · filed 2021-11-03 | |
| 2020-09-30 | $745.89M 10-Q · filed 2020-10-27 | |
| 2020-06-30 | $787.30M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $664.23M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $741.01M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $502.54M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $603.91M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $699.96M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $435.05M 10-K · filed 2020-02-14 | |
| 2018-09-30 | $483.25M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $541.40M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $529.46M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $224.03M 10-K · filed 2019-02-20 | $224.03M 10-K · filed 2018-02-21 |
| 2017-09-30 | $378.20M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $443.15M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $498.42M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $483.29M 10-K · filed 2018-02-21 | |
| 2016-09-30 | $451.00M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $427.10M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $472.82M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $515.21M 10-K · filed 2017-02-17 | |
| 2015-09-30 | $570.04M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $308.02M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $328.39M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $175.98M 10-K · filed 2016-02-26 | |
| 2014-09-30 | $195.06M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $143.63M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $161.10M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $52.79M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |